Please select from the following list of abstracts, representing the presentations given in Stockholm 2008 (IWWM-5) Session 8:
Incidence of disease transformation and development of MDS/AML in 165 patients with Waldenström’s Macroglobulinemia (WM) treated with fludarabine (F) -based regimen in three studies (French cooperative group on CLL/WM). Veronique Leblond, Jerome Tamburini, Vincent Levy, Sylvain Choquet, Anne_Laure Taksin, Frederic Maloisel, and Pierre Morel Hematology, Pitié-Salpêtrière Hospital, Paris, FRANCE.
Increased incidence of Transformation and Myelodysplasia/Acute Leukemia in patients with Waldenström’s Macroglobulinemia treated with Nucleoside Analogues. Xavier Leleu and Jacob Soumerai, Aldo Roccaro, Evdoxia Hatjiharissi, Zachary R. Hunter, Robert Manning, Bryan T. Ciccarelli, Antonio Sacco, Leukothea Ioakimidis, Sophia Adamia, Anne-Sophie Moreau, Christopher J. Patterson, Irene M. Ghobrial, and Steven P. Treon. Service des Maladies du Sang, Hopital Huriez, CHRU, Lille, FRANCE and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Success Rates of Autologous Stem Cell Collection in Patients with Waldenström Macroglobulinemia. Sheeba K. Thomas, M.D., Chitra Hosing, M.D., Kay B Delasalle, B.S., Maria B. Gavino, R.N., Uday R. Popat, M.D., Muzaffar H. Qazilbash, M.D., Sergio A. Giralt, M.D., Donna M. Weber, M.D. and Raymond Alexanian, M.D., Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, TX 77030, Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX, USA.
The Pro’s and Con’s of initial treatment with purine-nucleoside analogue-based combination therapies in patients with Waldenström macroglobulinemia. John Seymour, Peter MacCallum Cancer Centre, Melbourne, Australia.